Innate Pharma (IPHA) News Today → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free IPHA Stock Alerts $2.57 +0.07 (+2.80%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 10:17 AM | markets.businessinsider.comInnate Pharma Buy Rating Affirmed Amid Robust Pipeline and Financial StabilityMay 15 at 9:33 AM | marketbeat.comInnate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $11.50 price objective on shares of Innate Pharma in a report on Wednesday.May 15 at 1:00 AM | businesswire.comInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressMay 14 at 1:10 AM | finance.yahoo.comInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsMay 14 at 1:00 AM | businesswire.comInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsMay 12, 2024 | americanbankingnews.comInnate Pharma (IPHA) to Release Quarterly Earnings on TuesdayMay 8, 2024 | marketbeat.comInnate Pharma (IPHA) Scheduled to Post Quarterly Earnings on TuesdayInnate Pharma (NASDAQ:IPHA) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.May 7, 2024 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateApril 15, 2024 | businesswire.comInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsApril 15, 2024 | businesswire.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024April 11, 2024 | marketbeat.comInnate Pharma's (IPHA) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $11.50 target price on shares of Innate Pharma in a research note on Thursday.April 10, 2024 | businesswire.comInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateApril 9, 2024 | finance.yahoo.comInnate Pharma Announces Its Participation in Upcoming Investor ConferenceApril 9, 2024 | businesswire.comInnate Pharma Announces Its Participation in Upcoming Investor ConferenceApril 5, 2024 | finance.yahoo.comInnate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-FApril 5, 2024 | businesswire.comInnate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-FApril 2, 2024 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 13.6% in MarchInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 89,100 shares, a growth of 13.6% from the February 29th total of 78,400 shares. Based on an average daily volume of 11,700 shares, the short-interest ratio is presently 7.6 days.March 23, 2024 | seekingalpha.comInnate Pharma S.A. (IPHA) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | finance.yahoo.comInnate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $11.50 price target on shares of Innate Pharma in a research report on Friday.March 21, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Reports Full Year 2023 Financial Results and Business UpdateMarch 21, 2024 | businesswire.comInnate Pharma Reports Full Year 2023 Financial Results and Business UpdateMarch 19, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Announces Its Participation to Upcoming Investor ConferenceMarch 19, 2024 | businesswire.comInnate Pharma Announces Its Participation to Upcoming Investor ConferenceMarch 14, 2024 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial ResultsMarch 6, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024March 6, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's LymphomaMarch 6, 2024 | finance.yahoo.comInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s LymphomaMarch 6, 2024 | businesswire.comInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's LymphomaMarch 6, 2024 | businesswire.comInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024February 21, 2024 | businesswire.comInnate Pharma Announces Its Participation to Upcoming Investor ConferenceJanuary 30, 2024 | marketbeat.comInnate Pharma (NASDAQ:IPHA) Trading Up 0.4%Innate Pharma (NASDAQ:IPHA) Shares Up 0.4%January 12, 2024 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of January 1, 2024January 4, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical ProgramJanuary 4, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive BoardJanuary 4, 2024 | finance.yahoo.comInnate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive BoardJanuary 3, 2024 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest UpdateInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 54,000 shares, a drop of 5.9% from the November 30th total of 57,400 shares. Based on an average daily volume of 21,100 shares, the short-interest ratio is presently 2.6 days.December 31, 2023 | seekingalpha.comIPHYF Innate Pharma S.A.December 19, 2023 | morningstar.comInnate Pharma SA ADRDecember 18, 2023 | msn.comInnate Pharma CEO Mahjoubi to leave companyDecember 1, 2023 | benzinga.comInnate Pharma Stock (NASDAQ:IPHA), Analyst Ratings, Price Targets, PredictionsDecember 1, 2023 | benzinga.comInnate Pharma Stock (NASDAQ:IPHA) Dividends: History, Yield and DatesNovember 17, 2023 | markets.businessinsider.comPromising Clinical Outcomes and Strategic Partnerships Reinforce Buy Rating for Innate PharmaNovember 16, 2023 | markets.businessinsider.comPromising Updates on Lacutamab and ANKET Portfolio Fuel Buy Rating for Innate Pharma’s StockNovember 15, 2023 | finance.yahoo.comInnate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comInnate Pharma Reports Third Quarter 2023 Financial Results and Business UpdateOctober 9, 2023 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of October 3, 2023October 7, 2023 | businesswire.comInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour ...October 5, 2023 | finance.yahoo.comInnate Pharma Provides Update on Lacutamab Clinical ProgramSeptember 19, 2023 | marketbeat.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Down 8.1% in AugustInnate Pharma S.A. (NASDAQ:IPHA - Get Free Report) saw a significant decline in short interest in August. As of August 31st, there was short interest totalling 65,700 shares, a decline of 8.1% from the August 15th total of 71,500 shares. Based on an average trading volume of 12,600 shares, the short-interest ratio is presently 5.2 days. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. IPHA Media Mentions By Week IPHA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPHA News Sentiment▼0.390.55▲Average Medical News Sentiment IPHA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPHA Articles This Week▼81▲IPHA Articles Average Week Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADVM News KOD News IPSC News INMB News ABOS News ZURA News OPT News CMPX News CGEN News ELEV News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPHA) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
